Clinical Genomics Laboratory

Publications

Found 19 results

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

V

Kluk MJ, R Lindsley C, Aster JC, Lindeman NI, Szeto D, Hall D, Kuo FC. 2016. Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies.. J Mol Diagn. 18(4):507-15.

U

Saab J, Zia H, Mathew S, Kluk M, Narula N, Fernandes H. 2017. Utility of Genomic Analysis in Differentiating Synchronous and Metachronous Lung Adenocarcinomas from Primary Adenocarcinomas with Intrapulmonary Metastasis.. Transl Oncol. 10(3):442-449.

T

Chaligne R, Nam AS, Landau DA. 2019. TARGET-seq Takes Aim at Cancer Evolution through Multi-omics Single-Cell Genotyping and Transcriptomics.. Mol Cell. 73(6):1092-1094.

S

Nam AS, Kim K-T, Chaligne R, Izzo F, Ang C, Taylor J, Myers RM, Abu-Zeinah G, Brand R, Omans ND et al.. 2019. Somatic mutations and cell identity linked by Genotyping of Transcriptomes.. Nature. 571(7765):355-360.

R

Shanmugam V, Margolskee E, Kluk M, Giorgadze T, Orazi A. 2016. Rosai-Dorfman Disease Harboring an Activating KRAS K117N Missense Mutation.. Head Neck Pathol. 10(3):394-9.

Xing D, Liu Y, Park HJin, Baek I, Tran H, Cheang G, Novo J, Dillon J, Matoso A, Farmer E et al.. 2019. Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.. Hum Pathol. 92:67-80.

M

Kluk MJ, Abo RP, Brown RD, Kuo FC, Dal Cin P, Pozdnyakova O, Morgan EA, Lindeman NI, DeAngelo DJ, Aster JC. 2015. Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay.. Cold Spring Harb Mol Case Stud. 1(1):a000307.

Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, Chandramohan R, Liu ZYu, Won HH, Scott SN et al.. 2015. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.. J Mol Diagn. 17(3):251-64.

Baum JE, Sung K-J, Tran H, Song W, Ginter PS. 2019. Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With HRAS and PIK3CA Mutations by Next-Generation Sequencing.. Int J Surg Pathol. 27(4):441-445.

L

Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD. 2019. Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.. Br J Haematol. 186(6):801.

I

Sailer V, Eng KWa, Zhang T, Bareja R, Pisapia DJ, Sigaras A, Bhinder B, Romanel A, Wilkes D, Sticca E et al.. 2019. Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.. JCO Precis Oncol. 3

G

Rosenbaum JN, Bloom R, Forys JT, Hiken J, Armstrong JR, Branson J, McNulty S, Velu PD, Pepin K, Abel H et al.. 2018. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.. Mod Pathol. 31(5):791-808.

E

Ma J, Redmond D, Miyaguchi A, Nam AS, Nie K, Mathew S, Elemento O, Tam W. 2019. Exploring tumor clonal evolution in bone marrow of patients with diffuse large B-cell lymphoma by deep IGH sequencing and its potential relevance in relapse.. Blood Cancer J. 9(9):69.

Kluk MJ, Bagg A. 2019. Expedited Analysis and Reporting of Multiple Mutations that Modify Medical Management of Myeloid Malignancies: It's About (Turnaround) Time!. J Mol Diagn. 21(1):13-15.

D

Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al.. 2016. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1

C

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M et al.. 2019. Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.. Clin Cancer Res. 25(2):573-583.

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P et al.. 2020. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.. Cancer Immunol Res. 8(1):108-119.

Fernandez EM, Eng K, Beg S, Beltran H, Faltas BM, Mosquera JMiguel, Nanus DM, Pisapia DJ, Rao RA, Robinson BD et al.. 2019. Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.. JCO Precis Oncol. 3

Huang L, Fernandes H, Zia H, Tavassoli P, Rennert H, Pisapia D, Imielinski M, Sboner A, Rubin MA, Kluk M et al.. 2017. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations.. J Am Med Inform Assoc. 24(3):513-519.